Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 565 across all filing types
Latest filing 2026-05-14 Transaction in Own Shar…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Next Day Disclosure Return (Form FF305) under the Hong Kong Listing Rules, detailing changes in issued and treasury shares and a repurchase report on‐market (Section II) for Simcere Pharmaceutical Group. It provides a breakdown of shares repurchased for cancellation and an on‐exchange repurchase transaction (1,884,000 shares at HKD 11.66–11.43). This is not an investor presentation, earnings release, or general announcement but a transaction report on the company’s own share repurchases. Therefore, it falls under “Transaction in Own Shares” (Code: POS).
2026-05-14 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 92% confidence The document is a Hong Kong Stock Exchange Next Day Disclosure Return (form FF305) detailing changes in issued shares, repurchases for cancellation, and on-market sales of treasury shares under Main Board Rule 13.25A/10.06. It contains actual data on share buybacks and treasury share transactions, making it a detailed report of the company’s transactions in its own shares. This matches our category “Transaction in Own Shares” (POS).
2026-05-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings
2026-05-06 English
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR SIM0613 (LRRC15 ANTIBODY-DRUG CONJUGATE) ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings
2026-05-06 English
Next Day Disclosure Return
Regulatory Filings
2026-05-05 English
Next Day Disclosure Return
Regulatory Filings
2026-05-04 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.